- Charles River Laboratories Expands Access to CRADL® Contract Vivarium Space in Somerville
- Charles River Laboratories Announces Development of Nonclinical Virtual Control Groups with Sanofi to Reduce the Use of Animals in Research
- Charles River Laboratories to Present at William Blair and Jefferies Conferences
- Charles River Launches Viral Vector Tech Transfer Program to Safeguard Gene Therapy Development
- Charles River Laboratories Announces First-Quarter 2024 Results
- Charles River Launches Viral Vector Reference Materials to Streamline the Transition to GMP
- Charles River Laboratories Achieves 100% Renewable Electricity Usage Globally
- Charles River Laboratories Launches Alternative Methods Advancement Project to Reduce Reliance on Animal Testing
- Charles River Laboratories Schedules First-Quarter 2024 Earnings Release and Conference Call
- Charles River and Deciphex Launch Patholytix Foresight, a Transformative AI-Powered Decision Support Tool for Toxicologic Pathology
More ▼
Key statistics
On Thursday, Charles River Laboratories International Inc (CRL:NYQ) closed at 221.62, -19.41% below its 52-week high of 275.00, set on Mar 08, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 217.62 |
---|---|
High | 222.77 |
Low | 215.01 |
Bid | 217.08 |
Offer | 228.34 |
Previous close | 216.12 |
Average volume | 561.43k |
---|---|
Shares outstanding | 51.51m |
Free float | 51.00m |
P/E (TTM) | 24.46 |
Market cap | 10.74bn USD |
EPS (TTM) | 8.52 USD |
Data delayed at least 15 minutes, as of Jun 07 2024 00:00 BST.
More ▼